Jean-Pierre Bizzari holds a medical degree from the University of Nice (France) and trained as an oncologist at the Pitie Salpetriere in Paris, at Ontario Cancer Institute, and Montreal Mac Gill Cancer Center in Canada before joining the pharmaceutical industry in 1983 as Head of Oncology at the Institut de Recherches Internationales SERVIER (France). Between 1993 and 2008, Jean-Pierre Bizzari was initially Vice President of the clinical development in oncology at Rhône-Poulenc, and subsequently held the same position at Aventis. He served as Executive Vice President, and Clinical Oncology Development at Celgene from 2008 to 2015.
Some of Dr. Bizzari’s past accomplishments include, the clinical development of several anticancer agents such as Taxotere®, Eloxatin®, Irinotecan® Abraxane®, Muphoran®, Revlimid®, Vidaza®, Imnovid®.
As a world-renowned oncology expert, he is a member of the Scientific Advisory Board of the French National Cancer Institute (INCa) and European Organization of Research and Treatment of Cancer (EORTC) and Chairman of the New Drug Advisory Committee